The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

EMA committee recommends marketing approval for Novartis’ Kisqali to help reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Saturday, October 19, 202 ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible ...

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a ...

The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

Novartis on Friday announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...

Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion ...

Partly sunny, breezy and cool with spotty rain and mountain snow showers for Wednesday. The best chance for sunshine will be ...

Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

October marks Breast Cancer Awareness Month, an annual worldwide campaign to promote regular screening and early detection of breast cancer. According to the National Breast Cancer Foundation, one ...